ACM
ACRS icon

Asymmetry Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Asymmetry Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$2.89M Sell
198,493
-43,208
-18% -$655K 1.53% 21
2021
Q3 		$4.35M Sell
241,701
-74,133
-23% -$1.19M 2.62% 19
2021
Q2 		$5.55M Buy
+315,834
New +$7.17M 3.81% 12

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Asymmetry Capital Management's ACRS Position: Q4 2021 in Review

Asymmetry Capital Management reduced its Aclaris Therapeutics (ACRS) stake by 18% in Q4 2021, selling an estimated $655K and leaving 198,493 shares worth $2.89M. The position accounts for 1.53% of the portfolio, ranked #21.

Asymmetry Capital Management first reported a position in ACRS in Q2 2021 and has held it in 3 quarters since. The position peaked at $5.55M in Q2 2021. 133 funds tracked by Wall St. Rank hold ACRS as of Q4 2021.

  • Asymmetry Capital Management held 198,493 shares of Aclaris Therapeutics worth $2.89M as of Q4 2021.
  • Asymmetry Capital Management sold 43,208 Aclaris Therapeutics shares in Q4 2021, an estimated $655K.
  • Aclaris Therapeutics made up 1.53% of Asymmetry Capital Management's portfolio in Q4 2021, its #21 holding.
  • Asymmetry Capital Management first reported a position in Aclaris Therapeutics in Q2 2021 and has held it in 3 quarters since.
  • Asymmetry Capital Management's Aclaris Therapeutics position peaked at $5.55M in Q2 2021.
  • 133 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2021.

Based on Asymmetry Capital Management's 13F filing for Q4 2021, filed 19 Jan 2022.